- Thorne Research, Inc. v. Trustees Of Dartmouth CollegeAll claims unpatentablePTAB · May 31, 2022 · IPR2021-00268 · APJ John E Schneider · IPR · Final written decision
Claim 2 is unpatentable as anticipated by Stamler and, alternatively, obvious over Stamler.
RulingsFinal written decision- BurdenDecided for petitioner
“2. Anticipation2 “Under 35 U.S.C. § 102, every limitation of a claim must identically appear in a single prior art reference for it to anticipate the claim.” Gechter v. Davidson, 116 F.3d 1454, 1457 (Fed. Cir. 1997). “[U]nless a reference discloses within the four corners of the document not only all of the 2 As noted above, the pre-AIA provisions of 35 U.S.C. apply to the ’086 patent. the same way as recited in the claim, it cannot be said to prove prior invention of the thing claimed and, thus, cannot anticipate under 35 U.S.C. § 102.” Net MoneyIN, Inc. v. VeriSign, Inc., 545 F.3d 1359, 1371 (Fed. Cir. 2008).” slip op. at 8
- Disclosure Requirements (§112) › Written description (Ariad)Entitled to earlier dateDecided for patent owner
“Under § 120, a patent is entitled to the priority date of an earlier filed application if (1) the written description of the earlier filed application discloses the invention claimed in the later filed application sufficient to satisfy the requirements of § 112; (2) the applications have at least one common inventor; (3) the later application is filed before the issuance or abandonment of the earlier filed application; and (4) the later application contains a reference to the earlier filed application. In re NTP, Inc., 654 F.3d 1268, 1277 (Fed. Cir. 2011); see also 35 U.S.C. § 120 . As discussed above and in our Decision to Institute, the ’086 patent meets this criterion. While we agree with Petitioner that the face of the ’086 patent does not include a citation of the ‘701 application, the specification does contain a clear claim of priority back to the ’701 application. Ex. 1001, col. 1. ll. 7–13; Ex. 1004 1.” slip op. at 12
- Skill levelSkill level petitioner adoptedDecided for petitioner
“the art offered by Patent Owner in the ’1795 IPR, which, as noted above, also involved the ’086 patent, should apply to this proceeding, namely “someone with a Ph.D. in biochemistry or similar field in the pharmaceutical sciences, with familiarity and experience with pharmacokinetics.” Pet. 33. Patent Owner does not dispute Petitioner’s definition and, indeed, Patent Owner’s expert, Dr. Amiji, used the same definition in his analysis. Ex. 2014 ¶ 21. For purposes of this Decision, therefore, we adopt Petitioner’s description. We also note that the applied prior art reflects the appropriate level of skill at the time of the claimed invention and supports Petitioner’s definition. See Okajima v. Bourdeau, 261 F.3d 1350, 1355 (Fed. Cir. 2001).” slip op. at 14
- Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITATerm construed petitioner constructionDecided for petitioner
“We have considered the arguments presented by the parties, and find that our initial construction is proper for the reasons set forth in the ’1795 proceeding. Ex. 1018 12–14. We decline to adopt Patent Owner’s construction that calls for an isolation step separate from the process used to manufacture synthetic NR.” slip op. at 16
Patent outcomesUS 8,383,086 unpatentableClaim construction§ 102 anticipation§ 103 obviousness§ 112 disclosurecites KSR · GrahamPatents in suitUS 8,383,086 - Liquidia Technologies, Inc. v. United Therapeutics CorporationSome claims unpatentablePTAB · Oct 8, 2021 · IPR2020-00770 · APJ John E Schneider · IPR · Final written decision
Claims 1–5, 8, and 9 are unpatentable as obvious over Moriarty and Phares; claims 6 and 7 were not shown unpatentable over either asserted ground.
RulingsFinal written decision- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededDecided for patent owner
“Claim terms need only be construed to the extent necessary to resolve the controversy. Wellman, Inc. v. Eastman Chem. Co., 642 F.3d 1355, 1361 (Fed. Cir. 2011). Here, we do not need to define the outer bounds of the term “pharmaceutical batch” because the parties’ dispute over this term centers on the issue of storage stability.7 Patent Owner argues “the correct construction 6 The parties use the terms “purification” and “isolation” interchangeably in the papers. We use the term “isolation” in this Decision. 7 The parties agree on the “pharmaceutical” aspect of the term. We note the ’901 patent defines “pharmaceutically acceptable” as “being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.” Ex. 1001, 5:27–31.” slip op. at 19
- Claim Construction › Intrinsic evidence (Phillips canons) › Prosecution history disclaimer / disavowalTerm construed patent owner constructionDecided for patent owner
“[A]n invention is construed not only in the light of the claims, but also with reference to the file wrapper or prosecution history in the Patent Office.” Graham, 383 U.S. 1, 33. “The prosecution history of a related patent can be relevant if . . . it addresses a limitation in common with the patent in suit.” Advanced Cardiovascular Sys., Inc. v. Medtronic, Inc., 265 F.3d 1294, 1305 (Fed. Cir. 2001); see also Elkay Mfg. Co. v. Ebco Mfg. Co., 192 F.3d 973, 980 (Fed. Cir. 1999) (“When multiple patents derive from the same initial application, the prosecution history regarding a claim limitation in any patent that has issued applies with equal force to subsequently issued patents that contain the same claim limitation.”). Here, the Specification of the ’901 patent includes the same language “crude treprostinil salts can be stored as raw material at ambient temperature” addressed in the prosecution of the parent ’623 application. Ex. 1001, 17:5–6. More importantly, challenged claim 6 recites the same limitation “preparing a pharmaceutical product . . . after storage” the applicant expressly interpreted there. See Ex. 2028, 193. Because “the same claim limitation is at issue, prosecution disclaimer made on the same limitation in an ancestor application will attach,” the applicant’s interpretation of “storing”/“storage” during the prosecution of the ’623 application applies here. See Omega Eng’g, Inc., v. Raytek Corp., 334 F.3d 1314, 1333 (Fed. Cir. 2003). slip op. at 23
- Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITATerm construed patent owner constructionDecided for patent owner
“Sunovion Pharm., Inc. v. Teva Pharm. USA, Inc., 731 F.3d 1271, 1276 (Fed. Cir. 2013). Here, step (c) of challenged claim 1 requires “contacting the solution comprising treprostinil from step (b) with a base to form a salt of treprostinil.” Ex. 1001, 17:27–29 (emphasis added). The claim language itself, thus, dictates that the solution formed in step (b), and not treprostinil isolated from step (b), is the starting material for forming a salt in step (c). The Specification of the ’901 patent supports our determination. Indeed, the Specification touts that one of the advantages of the disclosed process is that “the treprostinil salts can be synthesized from the solution of treprostinil without isolation,” because “[t]he impurities carried over from intermediate steps (i.e. alkylation of triol and hydrolysis of benzindene nitrile) are removed during the carbon treatment and the salt formation step.” Ex. 1001, 17:1–11. As a result, we agree with the argument presented in the Patent Owner Response that “claim 1 requires the solution in which treprostinil is formed be used directly in the next salt-forming step without isolating treprostinil in between.” See PO Resp. 11.” slip op. at 27
- Skill levelSkill level board ownOther
“pharmaceutical manufacturing.” Id. at 23. We find Patent Owner’s definition of the skill level too narrow. Patent Owner relies on the declaration of Dr. Pinal, who testifies that the ’901 patent is “focused on the production of pharmaceutical compositions and products, on a commercial batch-size scale.” Ex. 2002 ¶ 91; see also id. ¶ 92 (opining that organic and medicinal chemists do not have the “requisite skill set for the large-scale manufacture” of drugs); PO Resp. 24 (arguing an ordinarily skilled artisan is aware of “problems encountered in preparing a commercial-scale pharmaceutical product”).” slip op. at 29
Patent outcomesUS 9,604,901 mixedClaim construction§ 103 obviousnesscites Phillips · KSR · GrahamPatents in suitUS 9,604,901 - Ty Inc. v. Softbelly’S, Inc.All claims unpatentablePTAB · Sep 10, 2021 · IPR2020-00689 · APJ John E Schneider · IPR · Final written decision
Claims 15 and 16 are unpatentable: claim 15 as anticipated by Ogawa and obvious over Ogawa and Masahiro; claim 16 as obvious over Ogawa with Cherk, and with Masahiro and Cherk.
RulingsFinal written decision- Skill levelSkill level petitioner adoptedDecided for petitioner
“We have considered the arguments presented by the parties and the evidence of record and are not persuaded that our original definition of a person of ordinary skill in the art was in error. While the claims at issue refer to an optical grade fabric, we note that the fabric is not the invention. Rather, as stated in the Specification, the field of the invention is “cleaning tools for electronic display screens, and more specifically to cleaning tools for computer display screens and the like.” Ex. 1001, col. 1, ll. 4–6. The claims further narrow the field of the invention to cleaning tools in the form of a doll-like structure. Id. at col. 6, l. 37. Based on the forgoing, we continue to apply the same definition of a person of ordinary skill in the art we used in our Decision on Institution. However, the findings and conclusions set forth below would have been the same had we instead adopted Patent Owner’s proposed definition.” slip op. at 9
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Term construed petitioner constructionDecided for petitioner
“We have considered the arguments presented by the parties and the evidence of record and conclude that Petitioner has the better position. The term “display screen,” as used in the challenged claims, refers to an intended use of the cleaning tool. As such, it does limit the scope of the claims. We begin by noting that the challenged claims are directed to a device or apparatus. Ex. 1002, col. 2, ll. 8–13. As such, the claims “cover what a device is, not what a device does.” Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1468 (1990). The preamble of both claims 6 and 11 read in part: “doll-like figure for cleaning or wiping the surface of a display screen.” Ex. 1001, col. 6, ll. 37–38; col. 7, ll. 1–2. Both claims end with the clause “providing a pliant cleaning tool for wiping a display screen.” Id. at col. 6, ll. 50–51; col. 7, ll. 13–14. These phrases are crafted in terms of a device for performing a specific function or use. This type of phrase has been found to recite an intended use and not a physical limitation. See Marrin v. Griffin, 599 F.3d 1290, 1294–96 (Fed. Cir. 2010). The recitation of the intended use in the body of the claim does not affect our analysis. The term for wiping a display screen still recites a use of the device that does not impart a structural limitation.” slip op. at 11
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)UnpatentableUnpatentable
“We have considered the testimony of both experts and the evidence of record and find Mrs. Ryan’s testimony to be more persuasive. Therefore, we agree with Petitioner that Ogawa discloses a wiping tool which has an inner chamber formed by a strip of optical grade fabric — the wipe portion — and a non-optical grade fabric — the gripping body. We give more weight to Mrs. Ryan’s testimony based on her extensive experience in designing plush toys. Ex. 1005 ¶¶ 3–5. Mrs. Ryan has worked in the area of plush toy design for over twenty-six years and has taught classes relating to plush toy design. Id. ¶¶ 3–4; page 40. In addition, Mrs. Ryan’s testimony regarding how one skilled in the art would envision the wiping tool of Ogawa is consistent with the evidence of record. For example, King4 teaches that teddy bears are formed by joining pieces of fabric creating an inner pocket into which stuffing is inserted. Ex. 1026, 7–12. Cockrill5 also teaches that teddy bears are traditionally made by cutting out the material, sewing the pieces together, and then stuffing the bears. Ex. 1025, 67.” slip op. at 17
- Expert testimonyPetitioner expert creditedPatent owner expert discountedDecided for petitioner
“We have considered the testimony of both experts and the evidence of record and find Mrs. Ryan’s testimony to be more persuasive. Therefore, we agree with Petitioner that Ogawa discloses a wiping tool which has an inner chamber formed by a strip of optical grade fabric — the wipe portion — and a non-optical grade fabric — the gripping body. We give more weight to Mrs. Ryan’s testimony based on her extensive experience in designing plush toys. Ex. 1005 ¶¶ 3–5. Mrs. Ryan has worked in the area of plush toy design for over twenty-six years and has taught classes relating to plush toy design. Id. ¶¶ 3–4; page 40. In addition, Mrs. Ryan’s testimony regarding how one skilled in the art would envision the wiping tool of Ogawa is consistent with the evidence of record. For example, King4 teaches that teddy bears are formed by joining pieces of fabric creating an inner pocket into which stuffing is inserted. Ex. 1026, 7–12. Cockrill5 also teaches that teddy bears are traditionally made by cutting out the material, sewing the pieces together, and then stuffing the bears. Ex. 1025, 67. Dr. Adanur’s experience and expertise appears to be primarily focused on textiles. Ex. 2005 ¶¶ 8–24. While Dr. Adanur testified that he has some experience in the area of plush toys, that experience appears to be limited to selection of fabric that could be used to manufacture plush toys and making several puppets at home to earn extra money. Ex. 1027, 52, 57–59, 78–79. In addition, Dr. Adanur does not cite to any evidence other than Ogawa to support his opinions as to what one skilled in the art would envision upon reading Ogawa. See Ex. 2005 ¶¶ 84–87. Patent Owner, however, contends that Ogawa is silent as to whether the tool has an inner chamber made from a piece of optical grade fabric and a piece of non-optical grade fabric. PO Resp. 1, 22. 4 King, Make Your Own Teddy Bears, 1985 (Ex. 1026) (“King”). 5 Cockrill, The Teddy Bear Encyclopedia, 1993 (Ex. 1025) (“Cockrill”).” slip op. at 17
Patent outcomesUS 6,195,831 unpatentableClaim construction§ 102 anticipation§ 103 obviousnesscites KSR · GrahamPatents in suitUS 6,195,831 - Rimfrost As v. Aker Biomarine Antarctic AsAll claims unpatentablePTAB · Jan 13, 2020 · IPR2018-01179 · APJ Erica A Franklin · IPR · Final written decision
Claims 33–61 are unpatentable as obvious across four grounds; the Board denied Patent Owner’s contingent motion to amend claims 75–84 as those substitute claims were also obvious.
RulingsFinal written decision- Skill levelSkill level petitioner adoptedDecided for petitioner
“At institution, we preliminarily adopted Petitioner’s definition of an ordinarily skilled artisan, and determined that the prior art itself was sufficient to demonstrate the level of ordinary skill in the art at the time of the invention. Inst. Dec. 9. We note that Patent Owner states that it “accepts [Petitioner’s] definition of a POSITA.” PO Resp. 16. Accordingly, for this Decision, we adopt Petitioner’s definition, while maintaining that the prior art demonstrates the appropriate level of ordinary skill in the art. See Okajima v. Bourdeau, 261 F.3d 1350, 1355 (Fed. Cir. 2001) (the prior art, itself, can reflect appropriate level of ordinary skill in art). Moreover, we have reviewed the credentials of Drs. Tallon and Hoem, and consider each of them to be qualified to provide their opinion on the level of skill and the knowledge of a person of ordinary skill in the art at the time of the invention.” slip op. at 11
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Term construed petitioner constructionDecided for petitioner
“As noted by Petitioner, the Board construed the phrase “greater than about 5% w/w” as meaning “greater than 4.5% w/w” in a Final Written Decision addressing similar claims of a related patent. Pet. Reply 12. Specifically, in IPR2018-00295, the Board’s analysis of the claim phrase “greater than about 5% w/w” of krill oil in the Final Written Decision reads as follows: Such broadening usages as ‘about’ must be given reasonable scope; they must be viewed by the decision maker as they would be understood by persons experienced in the field of the invention. Although it is rarely feasible to attach a precise limit to ‘about,’ the usage can usually be understood in light of the technology embodied in the invention.” Modine Mfg. Co. v. U.S. Int’l Trade Comm’n, 75 F.3d 1545, 1554 (Fed. Cir. 1996). After considering the parties’ arguments and reviewing the Specification of the ’765 patent, we conclude that Petitioner’s proposed construction is consistent with the intrinsic evidence. Although the ’765 patent does not explicitly address the issue of “about,” the meaning of the term can be discerned from a careful reading of the Specification. Example 8 of the ’765 patent reports the analysis of phospholipid fractions of a product of the invention and a commercially available Krill product. Ex. 1001, col. 31, l, 46–col. 32, l. 42. Table 22, reproduced above, reports the calculated values for the various phospholipids in values to a tenth of a percent. Id. at col. 32, ll. 18–38. In the discussion of the table, the values are rounded to the nearest whole number, not the nearest tenth. Id. at col. 32, ll. 11–15. This is consistent with the approach advanced by Petitioner. IPR2018-00295, Paper 35, 12.10 Similarly here, we find that although the Specification does not explicitly define the term “about,” its meaning may be discerned from the manner by which the Specification refers to reported values for phospholipid profiles of krill oil. Ex. 1001, 32:55–67 (Table 22). In the discussion of the lipids reported in Table 22, the values are rounded to the nearest whole number, not the nearest tenth. Id. at col. 32:47–52. This is more consistent with the approach advanced by Petitioner than by Patent Owner. Thus, as determined in that Final Written Decision, and for the reasons set forth therein, “the term ‘greater than about 5% w/w’ shall be construed to mean ‘greater than 4.5% w/w.’” IPR2018-00295, Paper 35, 13. Similarly, we construe the recitation in claim 33 requiring “greater than about 3% ether phospholipids” as meaning “greater than 2.5% ether phospholipids,” and we construe the recitation in claim 46 of “greater than 4% ether phospholipids” as meaning “greater than 3.5% phospholipids.” Although Petitioner and Patent Owner propose additional claim constructions, we determine that explicit construction of those additional claim terms is not necessary for purposes of this Decision.” slip op. at 14
- Obviousness (§103) › Motivation to combine / reasonable expectation of successMotivation foundReasonable expectation foundDecided for petitioner
“Based upon our review of the arguments, however, it does not appear that those differences between the claims analyzed in IPR2018-00295 and the challenged claims are material to the issue presented by Patent Owner regarding whether a person of ordinary skill in the art would combine ranges for specific lipid components in an extract from references that use different extraction techniques. Indeed, a side-by-side comparison of the argument set forth in Patent Owner’s Response filed in IPR2018-00295 and the Patent Owner’s Response filed here reveals that the same, virtually verbatim, arguments were made in both cases, absent changes in, e.g., citations and referring to Bottino II instead of Frick 1984 as disclosing a “non-selective” Folch extraction of krill. Compare IPR2018-00295, Paper 14, 14–22, with IPR2018-01179, Paper 12, 24–31. In the Final Written Decision, Patent Owner’s arguments, repeated here, were rejected. IPR2018-00295, Paper 35, 34–39. In any event, we do not apply collateral estoppel to this issue, as the parties have not fully briefed their positions in this proceeding. However, we determine that the analysis in the Final Written Decision for IPR2018-00295 regarding whether a skilled artisan would have been motivated to combine ranges for specific lipid components in an extract from references using different, i.e., “selective and non-selective” extraction techniques is applicable here. In particular, for the same reasons discussed in the IPR2018-00295 Final Written Decision, we accord persuasive weight to Dr. Tallon’s testimony that a POSITA would have known that the relative proportions of natural krill and hence the natural krill oil constituents could be varied in predictable ways by applying a single solvent or combination of solvents including super critical fluid extraction to selectively extract specific groups of lipid components based on their different solubility, and by blending these selective extracts in known and predictable ways to produce a desired krill oil composition. Ex. 1006 ¶¶ 104, 106, 110; see IPR2018-00295, Paper 35, 37–39. We note that Dr. Tallon provided similar testimony in IPR2017-00746, Ex. 1006 ¶ 212, which the Board also credited in determining that the claims of the ’877 patent, directed to a method of producing krill oil comprising extracting oil from denatured krill product with a polar solvent, IPR2017- 00746, Paper 23, 47–48, are unpatentable. Indeed, the Federal Circuit affirmed that Final Written Decision and the Board’s finding that “the lipid components of krill oil can be extracted using any number of suitable solvents, that the proportions of the components could be varied in predictable ways, and that the resulting extracts could be blended to produce a final krill oil product.” Aker Biomarine Antarctic, 786 F. App’x at 254. Moreover, as discussed in the IPR2018-00295 Final Written Decision, the ’765 patent, which shares the same Specification as the challenged patent, describes the compositions of the invention as being prepared by “blending the neutral and polar lipid extracts.” IPR2018-00295, Paper 35, 39, Ex. 1001, 12:34–35. As explained there, “[t]he Specification provides no further guidance regarding the blending step but instead relies on the” slip op. at 35
- PTAB / AIA Trials › Motions to amend / substitute claimsMotion to amend, deniedDenied
“Having considered the amended limitations of the substitute claims, and incorporating our analysis and conclusions regarding for the reiterated arguments regarding a motivation to combine and reasonable expectation of success from our discussion of the original claims, we conclude that the preponderance of the evidence demonstrates that substitute claims 75–82 are unpatentable as obvious over the combination of Yoshitomi, Catchpole, Bottino II, Sampalis I, Randolph, Sampalis II, and NKO; substitute claim 83 is unpatentable as obvious over the combination of Yoshitomi, Catchpole, Bottino II, Sampalis I, Fricke, Randolph, Sampalis II, and NKO; and substitute claim 84 is unpatentable as obvious over Yoshitomi, Catchpole, Bottino II, Sampalis I, Sampalis II, Randolph, and NKO. Accordingly, Patent Owner’s contingent Motion to Amend is denied. of this issue here is consistent with what was decided in that Final Written Decision. CONCLUSION For the foregoing reasons, we conclude that Petitioner has established by a preponderance of the evidence that claims 33–38, 40–43, 46–49, 51–52, 55–58, and 60 are unpatentable as obvious over Breivik II, Catchpole, Bottino II, and Sampalis I; claim 39 is unpatentable as obvious over Breivik II, Catchpole, Bottino II, Sampalis I, and Sampalis II; claims 44, 50, 53, and 59 are unpatentable as obvious over Breivik II, Catchpole, Bottino II, Sampalis I, and Fricke; and claims 45, 54, and 61 are unpatentable as obvious over Breivik II, Catchpole, Bottino II, Sampalis I, and Randolph. Additionally, we deny Patent Owner’s contingent Motion to Amend. V. ORDER Accordingly, it is hereby: ORDERED that based on a preponderance of the evidence, claims 33–61 of the ’453 patent are unpatentable; FURTHER ORDERED, Patent Owner’s Motion to Amend is denied;” slip op. at 51
Patent outcomesUS 9,375,453 unpatentableClaim construction§ 103 obviousnesscites KSR · GrahamPatents in suitUS 9,375,453 - Rimfrost As v. Aker Biomarine Antarctic AsAll claims unpatentablePTAB · Jan 13, 2020 · IPR2018-01178 · APJ Erica A Franklin · IPR · Final written decision
Claims 1–32 are unpatentable as obvious over the stated reference combinations; the contingent motion to amend substitute claims 62–74 is denied because those claims are unpatentable.
RulingsFinal written decision- Skill levelSkill level petitioner adoptedDecided for petitioner
“At institution, we preliminarily adopted Petitioner’s definition of an ordinarily skilled artisan, and determined that the prior art itself was sufficient to demonstrate the level of ordinary skill in the art at the time of the invention. Inst. Dec. 9. We note that Patent Owner states that it “accepts [Petitioner’s] definition of a POSITA.” PO Resp. 16. Accordingly, for this Decision, we adopt Petitioner’s definition, while maintaining that the prior art demonstrates the appropriate level of ordinary skill in the art. See Okajima v. Bourdeau, 261 F.3d 1350, 1355 (Fed. Cir. 2001) (the prior art, itself, can reflect appropriate level of ordinary skill in art). Moreover, we have reviewed the credentials of Drs. Tallon and Hoem, and consider each of them to be qualified to provide their opinion on the level of skill and the knowledge of a person of ordinary skill in the art at the time of the invention.” slip op. at 11
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Term construed petitioner constructionDecided for petitioner
“As noted by Petitioner, the Board construed the phrase “greater than about 5% w/w” as meaning “greater than 4.5% w/w” in a Final Written Decision addressing similar claims of a related patent. Pet. Reply 12. Specifically, in IPR2018-00295, the Board’s analysis of the claim phrase “greater than about 5% w/w” of krill oil in the Final Written Decision reads as follows: Such broadening usages as ‘about’ must be given reasonable scope; they must be viewed by the decision maker as they would be understood by persons experienced in the field of the invention. Although it is rarely feasible to attach a precise limit to ‘about,’ the usage can usually be understood in light of the technology embodied in the invention.” Modine Mfg. Co. v. U.S. Int’l Trade Comm’n, 75 F.3d 1545, 1554 (Fed. Cir. 1996). After considering the parties’ arguments and reviewing the Specification of the ’765 patent, we conclude that Petitioner’s proposed construction is consistent with the intrinsic evidence. Although the ’765 patent does not explicitly address the issue of “about,” the meaning of the term can be discerned from a careful reading of the Specification. Example 8 of the ’765 patent reports the analysis of phospholipid fractions of a product of the invention and a commercially available Krill product. Ex. 1001, col. 31, l, 46–col. 32, l. 42. Table 22, reproduced above, reports the calculated values for the various phospholipids in values to a tenth of a percent. Id. at col. 32, ll. 18–38. In the discussion of the table, the values are rounded to the nearest whole number, not the nearest tenth. Id. at col. 32, ll. 11–15. This is consistent with the approach advanced by Petitioner. IPR2018-00295, Paper 35, 12.10 Similarly here, we find that although the Specification does not explicitly define the term “about,” its meaning may be discerned from the manner by which the Specification refers to reported values for phospholipid profiles of krill oil. Ex. 1001, 32:55–67 (Table 22). In the discussion of the lipids reported in Table 22, the values are rounded to the nearest whole number, not the nearest tenth. Id. at 32:47–52. This is more consistent with the approach advanced by Petitioner than by Patent Owner. Thus, as determined in that Final Written Decision, and for the reasons set forth therein, “the term ‘greater than about 5% w/w’ shall be construed to mean ‘greater than 4.5% w/w.’” IPR2018-00295, Paper 35, 13. Similarly, we construe the recitation in claim 1 requiring “greater than about 3% ether phospholipids” as meaning “greater than 2.5% ether phospholipids,” and we construe the recitation in claim 14 of “greater than 4% ether phospholipids” as meaning “greater than 3.5% phospholipids.”” slip op. at 14
- Obviousness (§103) › Motivation to combine / reasonable expectation of successMotivation foundReasonable expectation foundDecided for petitioner
“Based on those prior art teachings, Petitioner asserts that the ordinarily skilled artisan also would have had a “reasonable expectation of producing a polar krill oil having the percentage of constituents as recited in the claims.” Id. at 53. Likewise, Dr. Tallon testifies that a person of ordinary skill in the art “would have known that the relative proportions of the natural krill and hence the natural krill oil constituents could be varied in predictable ways by applying a single solvent or combination of solvents . . . to selectively extract specific groups of lipid components . . . , and by blending these selective extracts in known and predictable ways to produce a desired krill oil composition,” indicating that an ordinarily skilled artisan would have had a reason to combine the teachings of the cited references and a reasonable expectation of success in doing so in a manner that yields the claimed invention. Ex. 1006 ¶ 104. Based on our review of the record as a whole, we determine that a preponderance of the evidence supports Petitioner’s contention that an ordinarily skilled artisan would have had reason to combine the teachings of Breivik II, Catchpole, Bottino II, and Sampalis I, with a reasonable expectation of successfully arriving at the inventions of claims 1–3, 5–10, 12, 14–17, 19–20, 23–26, 28, and 30–32. Next, we address Patent Owner’s arguments and Petitioner’s assertion of collateral estoppel.” slip op. at 30
- BurdenUnpatentable
“Based on the foregoing, we conclude that Petitioner has established by a preponderance of the evidence that claims 1–3, 5–10, 12, 14–17, 19–20, 23–26, 28, and 30–32 are unpatentable over the combined teachings of Breivik II, Catchpole, Bottino II, and Sampalis I. F. Obviousness of Remaining Grounds Based upon Combinations including Breivik II, Catchpole, Bottino II and Sampalis I Each of the three remaining grounds rely upon similar combinations of Breivik II, Catchpole, Bottino II, and Sampalis I, as set forth in the ground analyzed above, in Section II. E. Pet. 7, 56–66. The remaining grounds combine additional references to address various limitations of dependent claims 4, 11, 13, 18, 21, 22, 27, and 29. Id. Patent Owner challenges those additional grounds only by relying on its arguments presented with respect to the ground based upon Breivik II, Catchpole, Bottino II, and Sampalis I. PO Resp. 33–35. According to Patent Owner, the additional references relied upon in the remaining grounds do not “cure the deficiencies noted above for the core four references.” Id. We have considered the combined teachings of the cited references for each of the remaining grounds, along with Petitioner’s arguments and Dr. Tallon’s testimony and, based on the record as a whole, we determine that Petitioner has established by a preponderance of the evidence that claims 4, 11, 13, 18, 21, 22, 27, and 29 are unpatentable over those combined teachings for the reasons discussed herein regarding the combination of Breivik II, Catchpole, Bottino II, and Sampalis I, and based upon Petitioner’s additional evidence and arguments in each of the remaining grounds, which we adopt as our own. See Pet. 56–66; Ex. 1006 ¶¶ 439–457.” slip op. at 37
Patent outcomesUS 9,375,453 unpatentableClaim construction§ 103 obviousnesscites KSR · GrahamPatents in suitUS 9,375,453
Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.